

Zoetis Dermatology Has You Covered

Trust our 10-year history of treating millions of dogs with allergic and atopic dermatitis



apoquel
chewable
(oclacitinib chewable tablet)

apoquel
(oclacitinib tablet)



CYTOPOINT

Prescribed for more than 15M dogs over 10 years^{1*}

Prescribed for more than 9M dogs over 8 years¹

Fast itch relief that is safe and easy to use

A great option for first-time and acute patients

- Rapid control of allergic itch starting in 4 hours^{2†}
- An immunomodulator that provides significant reduction of inflammation due to allergic dermatitis³
- A selective JAK1 inhibitor that targets the cytokines that cause itch and inflammation due to allergic dermatitis⁴
- Well-established safety history with Apoquel in dogs over 12 months⁵
- Apoquel Chewable is a highly palatable, treat-like formulation that pet owners prefer^{6‡,7}

*Apoquel tablet launched May 2013, Apoquel Chewable launched October 2023.

†Data for Apoquel Chewable based on a model study for canine flea allergic dermatitis.

‡Responses based on owner review of Apoquel tablet and Apoquel Chewable product profiles in a survey. N=262 pet owners.



Easily switch between treatments depending on the pet's response or the pet owner's preference

Lifelong choice for lasting pruritus control

A great option for seasonal and chronic patients

- Allergic pruritus control that lasts 4–8 weeks⁸
- Safe for dogs of all ages and can be used in dogs with comorbidities⁹
- Most dogs on Cytopoint required fewer concomitant medications such as steroids, antibiotics, and topicals¹⁰
- Cytopoint's in-office injection ensures compliance and improves quality of life for dogs and their owners¹⁰
- Veterinarians appreciate the ongoing patient monitoring that comes with regular office-based injections





apoquel
chewable
(oclacitinib chewable tablet)

apoquel
(oclacitinib tablet)

CYTOPOINT

APOQUEL AND APOQUEL CHEWABLE IMPORTANT SAFETY INFORMATION: Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines. See full Prescribing Information at [ApoquelTabletAndChewablePI.com](https://www.zoetis.com/ApoquelTabletAndChewablePI.com).

Apoquel and Apoquel Chewable Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Cytopoint Indications: Cytopoint has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

References: **1.** Kynetec PetTrak – GAH-284: Unique Patient Count Since Launch Custom Report: Apoquel and Cytopoint: January 2014 – February 2024. **2.** Study Report No. A162R-US-21-C32, 2022, Zoetis Inc. **3.** Data on file: Study Report A161C-US-21-C02, 2022, Zoetis Inc. **4.** Gonzales AJ, Bowman JW, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. *J Vet Pharmacol Ther.* 2014;37(4):317-324. **5.** Data on file, A Five-Year Post-Approval Safety Review for APOQUEL® in the US (May 2013 to August 2018), Zoetis Inc. **6.** Data on file, ZMR: Adelphi/PROVE: Pet Owner Preferences Chewable vs. Conventional Canine Pruritus, Zoetis Services LLC, March 2023. **7.** Visser M, Walsh K, King V, et al. Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis. *BMC Vet Res.* 2022;18(1):103. **8.** Michels GM, Ramsey DS, Walsh KF, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. *Vet Dermatol.* 2016;27(6):478-e129. **9.** Michels GM, Walsh KF, Kryda KA, et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. *Vet Dermatol.* 2016;27(6):505-e136. **10.** Data on file, Study Report No. 17SORORDER-01-01, 2018, Zoetis Inc.